Avenzo Therapeutics Deal History & Licensing Activity
Avenzo Therapeutics is a biotech headquartered in US. Over the past three years, Avenzo Therapeutics has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals). The company currently has 4 active clinical trials, primarily in Immunology.
Deals (12mo)
1
Active Trials
4
Top Modality
Small Molecules
Focus Area
Immunology
Avenzo Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Avenzo Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| BTK inhibitor | Travere Therapeutics | Small Molecules | Unknown | license | Jun 3, 2026 |
| rare disease / immunology program | Rallybio | Other | Unknown | collaboration | Jun 1, 2026 |
| next-generation oncology pipeline | Rallybio | ADC | Unknown | acquisition |
Avenzo Therapeutics Pipeline Focus
Therapeutic areas and modalities where Avenzo Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Avenzo Therapeutics Clinical Pipeline
Avenzo Therapeutics has 4 active clinical trials across 1 development phase.
4
Phase 1
See How Your Asset Matches Avenzo Therapeutics's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Avenzo Therapeutics Licensing & Deal Activity
Avenzo Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Avenzo Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Avenzo Therapeutics include Immunology (4 deals and trials), Solid Tumors (4 deals and trials), and Oncology (2 deals and trials). In terms of modality, Avenzo Therapeutics has shown particular interest in small molecules, other, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Avenzo Therapeutics and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Avenzo Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.